On 9 March 2022 Civil Society Representatives to the Therapeutics Pillar of the ACT-A sent a letter to Albert Bourla (Chairman and Chief Executive Officer at Pfizer) expressing concerns about several global access concerns regarding Paxlovid.
A copy of the letter can be found here.
